Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis | MediciNova, Inc.

コンテンツへスキップ

About Us

　　Message from CEO

　　Our Mission

　　Company Profile

　　Management Team

Clinical Development

　　Ongoing Clinical Studies

　 MN-166 (Ibudilast)

　　　　About MN-166 (Ibudilast)

　　　　ALS

　　　　Oncology / Glioblastoma

　　　　DCM

　　　　CIPN

　　　　ARDS / Lung Injury

　 MN-001 (Tipelukast)

　　　　About MN-001（Tipelukast)

　　　　NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia

Investor Relations

　　Press Release

　　Media Archive

　　Annual Report

　　SEC filing

　　Stock Quote -TSE

　　Stock Quote -Nasdaq

　　Historical Price Lookup

　　Investment Calculator

　　Analyst Coverage

　　Corporate Governance

　　Information Request

Presentation

　　Corporate Presentation & Resarch Reports

　MN-166 Presentation

　　　　Progressive Multiple Sclerosis (Progressive MS)

　　　　Amyotrophic Lateral Sclerosis (ALS)

　　　　Oncology / Glioblastoma

　　　　Substance Dependence and Addiction

　　　　MN-166 (ibudilast) News Articles

　　　　MN-166 (ibudilast) Publications

　　MN-001 Presentation

Contact Us

　　Contact Us

About Us
Clinical Development
Investor Relations
Presentation
Contact Us

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis

MN-166 Publications

2018.08.302025.10.17

MediciNova, Inc.

関連記事

MN-166 Publications

Ibudilast protects against neuronal damage induced by glutamate in cultured hippocampal neurons

MN-166 Publications

Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?

MN-166 Presentation

MN-166(ibudilast) for Progressive MS : American Academy of Neurology (AAN) 2015 Poster

MN-166 Presentation

MN-166(ibudilast) for Progressive MS : SPRINT-MS Phase 2b Trial Top-Line Results ECTRIMS 2017 Presentation

MN-166 Publications

Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia

MN-166 Presentation

MN-166(ibudilast) for Opioid Dependence : American Academy of Neurology (AAN) Poster

MN-166(ibudilast) for Progressive MS : SPRINT-MS Phase 2b Trial Disability Date ACTRIMS 2018 Poster

MN-166(ibudilast)for ALS : International Symposium on ALS-MND 2018 Presentation

Copyright © 2021 MEDICINOVA, Inc. All Rights Reserved. | Terms of Use | Privacy Policy

メニュー
検索